Mesoblast (NASDAQ:MESO) Rating Lowered to Hold at Jefferies Financial Group

Mesoblast (NASDAQ:MESO) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, MarketBeat.com reports.

Separately, Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Mesoblast currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Performance

MESO opened at $15.62 on Friday. The stock has a fifty day simple moving average of $11.32 and a two-hundred day simple moving average of $13.55. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 0.22. Mesoblast has a 12-month low of $5.78 and a 12-month high of $22.00.

Hedge Funds Weigh In On Mesoblast

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC purchased a new stake in shares of Mesoblast during the fourth quarter valued at $38,000. JPMorgan Chase & Co. purchased a new stake in shares of Mesoblast during the fourth quarter valued at $50,000. BNP Paribas Financial Markets boosted its position in shares of Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after buying an additional 2,597 shares during the last quarter. Advisors Preferred LLC boosted its position in shares of Mesoblast by 224.9% during the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company’s stock valued at $54,000 after buying an additional 3,169 shares during the last quarter. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Mesoblast during the fourth quarter valued at $88,000. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.